All In Biotech

Drug Trial Radar · NCT03931317

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

A Randomized, Single Center, Masked, Crossover Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity in Patients With Ocular Hypertension or Primary Open Angle Glaucoma

Last checked: Nov 20, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Dec 3, 2018

Primary completion

May 20, 2021

Study completion Mar 1, 2023

Sponsor

Lead sponsor
University of California, San DiegoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bausch & Lomb Incorporated
First posted
Apr 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
Single (investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this research study is to compare the effect of Latanoprostene Bunod and Timolol on eye pressure and blood vessels of the back of the eye.

Conditions

  • OAG - Open-Angle Glaucoma
  • OHT - Ocular Hypertension

Interventions

  • Latanoprostene bunod 0.024% QDDrug

    This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.

  • Timolol maleate 0.5% BIDDrug

    This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. retinal blood vessel density (peripapillary and macular)Time frame: Through study completion, an average of 11 to 19 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCSD Shiley Eye Institute

    La Jolla, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.